Nonetheless, in a secondary analysis of the diabetes endpoint in the CANVOS trial, blockade of IL-1β with canakinumab over a median period of 3.7 years did not reduce incident diabetes [36]. This evidence concerns the gene IL1B and diabetes mellitus.